Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 1/20 | 0.50 |
| ▸ | RARB | P10826 | 1/20 | 0.50 |
| ▸ | RARG | P13631 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17301261 | 0.92 | NR1H4 (0.53) | RARARARBRARGKMT2AMAPT | |
| SCHEMBL20548503 | 0.92 | MAPT (0.54) | KMT2AMAPTTDP1L3MBTL1NPC1 | |
| SCHEMBL20548872 | 0.91 | KMT2A (0.56) | RARARARBRARGKMT2AMAPT | |
| SCHEMBL13463776 | 0.85 | KMT2A (0.57) | KMT2AMAPTL3MBTL1NPC1RAB9A | |
| SCHEMBL20548705 | 0.85 | RARA (0.50) | RARARARBRARGKMT2AMAPT | |
| SCHEMBL13463777 | 0.84 | KMT2A (0.56) | KMT2AMAPTTDP1L3MBTL1NPC1 | |
| SCHEMBL14580105 | 0.83 | RARA (0.60) | RARARARBRARGKMT2AMAPT | |
| SCHEMBL20548681 | 0.82 | LMNA (0.60) | KMT2AMAPTNR1H4ALDH1A1GAA | |
| SCHEMBL17301270 | 0.81 | KMT2A (0.52) | KMT2AMAPTL3MBTL1NPC1RAB9A | |
| SCHEMBL14877882 | 0.81 | NR1H4 (0.55) | KMT2AMAPTNPC1RAB9ANR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190022049-A1 | HYDROQUINONE COMPOUNDS, PREPARATION METHODS THEREFOR, AND USE IN ANTI-TUMOR OR IMMUNOMODULATION THERAPY | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY, ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2019-01-24 | — | — | US | claimed |
| US-11738000-B2 | Hydroquinone compounds, preparation methods therefor, and use in anti-tumor or immunomodulation therapy | BIOMEDICAL ANALYSIS CENTER, ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2023-08-29 | — | — | US | disclosed |
| US-20210008022-A1 | HYDROQUINONE COMPOUNDS, PREPARATION METHODS THEREFOR, AND USE IN ANTI-TUMOR OR IMMUNOMODULATION THERAPY | BIOMEDICAL ANALYSIS CENTER, ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2021-01-14 | — | — | US | disclosed |
| US-10786481-B2 | Hydroquinone compounds, preparation methods therefor, and use in anti-tumor or immunomodulation therapy | BIOMEDICAL ANAYLSIS CENTER, ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2020-09-29 | — | — | US | disclosed |
| US-20190022049-A1 | HYDROQUINONE COMPOUNDS, PREPARATION METHODS THEREFOR, AND USE IN ANTI-TUMOR OR IMMUNOMODULATION THERAPY | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY, ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2019-01-24 | — | — | US | disclosed |
| EP-3398934-A1 | HYDROQUINONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION IN TUMOUR RESISTANCE OR IMMUNOMODULATION | Biomedical Analysis Center Academy of Military Medical Sciences (CN) | 2018-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190022049-A1 | HYDROQUINONE COMPOUNDS, PREPARATION METHODS THEREFOR, AND USE IN ANTI-TUMOR OR IMMUNOMODULATION THERAPY | WEE2, WEE1, NQO1 | RARA 3337/4885RARB 3453/4885RARG 2872/4885 |
| US-20210008022-A1 | HYDROQUINONE COMPOUNDS, PREPARATION METHODS THEREFOR, AND USE IN ANTI-TUMOR OR IMMUNOMODULATION THERAPY | WEE2, WEE1, NQO1 | RARA 3375/4885RARB 3460/4885RARG 2733/4885 |
| US-10786481-B2 | Hydroquinone compounds, preparation methods therefor, and use in anti-tumor or immunomodulation therapy | WEE2, WEE1, NQO1 | RARA 3337/4885RARB 3453/4885RARG 2872/4885 |
| US-11738000-B2 | Hydroquinone compounds, preparation methods therefor, and use in anti-tumor or immunomodulation therapy | WEE2, WEE1, NQO1 | RARA 3375/4885RARB 3460/4885RARG 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.